You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》高盛上調聯邦制藥(03933.HK)目標價至6.5元 評級「中性」
阿思達克 04-12 11:01
高盛發表報告指,聯邦制藥(03933.HK)去年下半年銷售為45億元人民幣,按年增長3.8%,表現遜於該行預期的48億元人民幣,主要由於中間體青黴素G鉀有四個月的生產中斷;及醫院探訪恢復緩慢和疫情後呼吸疾病減少,令抗生素銷售下跌27.8%,對比2019年下半年為增長27%。

該行表示,聯邦制去年下半年盈利則為4.98億元人民幣,表現符合該行預期的4.85億元人民幣,主因網上市場推廣成本節約,令銷售開支有更佳的控制;行政及財務成本減少;及稅率下降。

高盛指,上調聯邦制藥目標價,由6.2元升至6.5元,維持「中性」評級,並調升聯邦制藥今明兩年盈利預測分別16.2%及5.4%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account